Cardiff Oncology Operating Margin vs. Net Income
| CRDF Stock | USD 2.94 0.04 1.38% |
Cardiff Oncology Operating Profit Margin |
|
For Cardiff Oncology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cardiff Oncology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cardiff Oncology utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cardiff Oncology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cardiff Oncology over time as well as its relative position and ranking within its peers.
Check out Trending Equities. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiff Oncology. If investors know Cardiff will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiff Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.79) | Revenue Per Share | Quarterly Revenue Growth (0.27) | Return On Assets | Return On Equity |
The market value of Cardiff Oncology is measured differently than its book value, which is the value of Cardiff that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiff Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cardiff Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiff Oncology's market value can be influenced by many factors that don't directly affect Cardiff Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiff Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiff Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiff Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cardiff Oncology Net Income vs. Operating Margin Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Cardiff Oncology's current stock value. Our valuation model uses many indicators to compare Cardiff Oncology value to that of its competitors to determine the firm's financial worth. Cardiff Oncology is rated fourth in operating margin category among its peers. It is rated fifth in net income category among its peers . At this time, Cardiff Oncology's Operating Profit Margin is most likely to decrease significantly in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value Cardiff Oncology by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Cardiff Net Income vs. Operating Margin
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Cardiff Oncology |
| = | (99.78) % |
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Cardiff Oncology |
| = | (45.43 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Cardiff Net Income Comparison
Cardiff Oncology is currently under evaluation in net income category among its peers.
Cardiff Oncology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Cardiff Oncology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cardiff Oncology will eventually generate negative long term returns. The profitability progress is the general direction of Cardiff Oncology's change in net profit over the period of time. It can combine multiple indicators of Cardiff Oncology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 30.6 K | 32.1 K | |
| Operating Income | -43.8 M | -41.6 M | |
| Income Before Tax | -40.9 M | -38.8 M | |
| Total Other Income Expense Net | 3.7 M | 3.9 M | |
| Net Loss | -40.9 M | -38.8 M | |
| Income Tax Expense | -21.6 K | -20.5 K | |
| Net Loss | -40.9 M | -42.9 M | |
| Non Operating Income Net Other | 1.4 M | 1.4 M | |
| Net Loss | -34.9 M | -36.6 M | |
| Interest Income | 3.7 M | 3.9 M | |
| Net Interest Income | 3.7 M | 3.9 M | |
| Change To Netincome | 3.8 M | 2.4 M | |
| Net Loss | (0.86) | (0.90) | |
| Income Quality | 0.75 | 0.58 | |
| Net Income Per E B T | 1.13 | 1.10 |
Cardiff Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Cardiff Oncology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cardiff Oncology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cardiff Oncology's important profitability drivers and their relationship over time.
Cardiff Oncology Earnings Estimation Breakdown
The calculation of Cardiff Oncology's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Cardiff Oncology is estimated to be -0.185 with the future projection ranging from a low of -0.21 to a high of -0.16. Please be aware that this consensus of annual earnings estimates for Cardiff Oncology is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.21 Lowest | Expected EPS | -0.16 Highest |
Cardiff Oncology Earnings Projection Consensus
Suppose the current estimates of Cardiff Oncology's value are higher than the current market price of the Cardiff Oncology stock. In this case, investors may conclude that Cardiff Oncology is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Cardiff Oncology's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 9 | 77.99% | 0.0 | -0.185 | -0.79 |
Cardiff Oncology Earnings per Share Projection vs Actual
Actual Earning per Share of Cardiff Oncology refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Cardiff Oncology predict the company's earnings will be in the future. The higher the earnings per share of Cardiff Oncology, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Cardiff Oncology Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Cardiff Oncology, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Cardiff Oncology should always be considered in relation to other companies to make a more educated investment decision.Cardiff Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Cardiff Oncology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-11-06 | 2025-09-30 | -0.21 | -0.17 | 0.04 | 19 | ||
2025-07-29 | 2025-06-30 | -0.19 | -0.21 | -0.02 | 10 | ||
2025-05-08 | 2025-03-31 | -0.19 | -0.2 | -0.01 | 5 | ||
2025-02-26 | 2024-12-31 | -0.2475 | -0.21 | 0.0375 | 15 | ||
2024-10-31 | 2024-09-30 | -0.27 | -0.25 | 0.02 | 7 | ||
2024-08-08 | 2024-06-30 | -0.25 | -0.26 | -0.01 | 4 | ||
2024-05-02 | 2024-03-31 | -0.25 | -0.22 | 0.03 | 12 | ||
2024-02-29 | 2023-12-31 | -0.28 | -0.21 | 0.07 | 25 | ||
2023-11-02 | 2023-09-30 | -0.28 | -0.22 | 0.06 | 21 | ||
2023-08-09 | 2023-06-30 | -0.26 | -0.25 | 0.01 | 3 | ||
2023-05-04 | 2023-03-31 | -0.23 | -0.25 | -0.02 | 8 | ||
2023-03-02 | 2022-12-31 | -0.23 | -0.2 | 0.03 | 13 | ||
2022-11-03 | 2022-09-30 | -0.26 | -0.2 | 0.06 | 23 | ||
2022-08-04 | 2022-06-30 | -0.25 | -0.24 | 0.01 | 4 | ||
2022-05-05 | 2022-03-31 | -0.23 | -0.25 | -0.02 | 8 | ||
2022-02-24 | 2021-12-31 | -0.17 | -0.23 | -0.06 | 35 | ||
2021-11-04 | 2021-09-30 | -0.17 | -0.17 | 0.0 | 0 | ||
2021-08-05 | 2021-06-30 | -0.15 | -0.17 | -0.02 | 13 | ||
2021-05-06 | 2021-03-31 | -0.15 | -0.14 | 0.01 | 6 | ||
2021-02-25 | 2020-12-31 | -0.14 | -0.19 | -0.05 | 35 | ||
2020-11-05 | 2020-09-30 | -0.19 | -0.19 | 0.0 | 0 | ||
2020-08-11 | 2020-06-30 | -0.24 | -0.51 | -0.27 | 112 | ||
2020-05-07 | 2020-03-31 | -0.41 | -0.41 | 0.0 | 0 | ||
2020-02-27 | 2019-12-31 | -0.57 | -0.51 | 0.06 | 10 | ||
2019-11-07 | 2019-09-30 | -0.84 | -0.71 | 0.13 | 15 | ||
2019-08-08 | 2019-06-30 | -0.53 | -0.79 | -0.26 | 49 | ||
2019-05-07 | 2019-03-31 | -1.07 | -1.02 | 0.05 | 4 | ||
2019-03-06 | 2018-12-31 | -1.05 | -1.09 | -0.04 | 3 | ||
2018-11-07 | 2018-09-30 | -1.98 | -1.08 | 0.9 | 45 | ||
2018-08-03 | 2018-06-30 | -1.98 | -2.64 | -0.66 | 33 | ||
2018-05-08 | 2018-03-31 | -8.28 | -6.48 | 1.8 | 21 | ||
2018-02-26 | 2017-12-31 | -9 | -4.32 | 4.68 | 52 | ||
2017-11-09 | 2017-09-30 | -10.08 | -8.64 | 1.44 | 14 | ||
2017-08-09 | 2017-06-30 | -10.8 | -10.08 | 0.72 | 6 | ||
2017-05-10 | 2017-03-31 | -17.28 | -19.44 | -2.16 | 12 | ||
2017-03-15 | 2016-12-31 | -23.04 | -18.0 | 5.04 | 21 | ||
2016-11-09 | 2016-09-30 | -23.4 | -24.48 | -1.08 | 4 | ||
2016-08-04 | 2016-06-30 | -22.32 | -24.48 | -2.16 | 9 | ||
2016-05-10 | 2016-03-31 | -21.17 | -25.2 | -4.03 | 19 | ||
2016-03-10 | 2015-12-31 | -17.88 | -18.0 | -0.12 | 0 | ||
2015-11-09 | 2015-09-30 | -19.58 | -7.2 | 12.38 | 63 | ||
2015-08-10 | 2015-06-30 | -17.52 | -29.52 | -12.0 | 68 | ||
2015-05-05 | 2015-03-31 | -17.46 | -23.76 | -6.3 | 36 | ||
2015-03-12 | 2014-12-31 | -18.36 | -18.0 | 0.36 | 1 | ||
2014-11-06 | 2014-09-30 | -17.64 | -20.16 | -2.52 | 14 | ||
2014-08-07 | 2014-06-30 | -14.88 | -4.32 | 10.56 | 70 | ||
2014-05-12 | 2014-03-31 | -14.04 | -12.24 | 1.8 | 12 | ||
2014-03-17 | 2013-12-31 | -13.68 | -3.6 | 10.08 | 73 | ||
2013-11-14 | 2013-09-30 | -16.2 | -18.0 | -1.8 | 11 | ||
2013-08-14 | 2013-06-30 | -10.44 | -10.8 | -0.36 | 3 | ||
2013-05-14 | 2013-03-31 | -6.84 | -5.04 | 1.8 | 26 | ||
2013-03-31 | 2012-12-31 | -6.12 | -7.2 | -1.08 | 17 |
Use Cardiff Oncology in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cardiff Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardiff Oncology will appreciate offsetting losses from the drop in the long position's value.Cardiff Oncology Pair Trading
Cardiff Oncology Pair Trading Analysis
The ability to find closely correlated positions to Cardiff Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cardiff Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cardiff Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cardiff Oncology to buy it.
The correlation of Cardiff Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cardiff Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cardiff Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cardiff Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Cardiff Oncology position
In addition to having Cardiff Oncology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Conservative Funds Thematic Idea Now
Conservative Funds
Funds or Etfs that invest using buy-and-hold investment strategy in companies with consistent growth over many years of operation. The Conservative Funds theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Conservative Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
To fully project Cardiff Oncology's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Cardiff Oncology at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Cardiff Oncology's income statement, its balance sheet, and the statement of cash flows.